Lv1
10 积分 2023-12-06 加入
Interstitial lung disease risk of anaplastic lymphoma kinase tyrosine kinase inhibitor treatment of non-small cell lung cancer: a real-world pharmacovigilance study
2天前
已完结
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
12天前
已完结
ALK in cancer: from function to therapeutic targeting
13天前
已完结
EP.12B.14 Platinum-Pemetrexed Chemotherapy and Lorlatinib Combination in Advanced ALK Positive NSCLC Progressing to Lorlatinib: A Case Series
30天前
已关闭
EP.12B.14 Platinum-Pemetrexed Chemotherapy and Lorlatinib Combination in Advanced ALK Positive NSCLC Progressing to Lorlatinib: A Case Series
30天前
已关闭
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease
30天前
已完结
Comprehensive genomic analysis reveals molecular heterogeneity in pediatric ALK-positive anaplastic large cell lymphoma
3个月前
已完结
Combination carboplatin and nab-paclitaxel as a first-line treatment for advanced thymic carcinoma
3个月前
已完结
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
3个月前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
3个月前
已完结
皖公网安备34019202002308
